KLK3 and COVID-19: The study period included the peak of the COVID-19 pandemic, during which there was a decrease in PSA testing.15 However, the distribution of PSA levels in our study was unchanged compared with the period before the pandemic, and it is unlikely that this factor would be a confounder influencing our results in a favorable way for the MRI-first path.